SECISBP2L and lung carcinoma: Mechanistically, this protein could negatively modulate AURKA activity by directly repressing its kinase activity or reducing the levels of AURK and, importantly, restrain cell proliferation of human lung cancer cells indicating the therapeutic potential of SLAN in AURKA-associated cancer development.